Metagenomic and Metabolomic Analysis in Primary Aldosteronism Associated with Obstructive Sleep Apnea
-
By
-
Li Yang
-
Yi Tao
-
Yan He
-
Shijie Liu
-
Lulu Gan
-
Anni Dai
-
Qing Ni
-
Yun Wang
-
Fengping Li
-
Qian Liu
-
Yang Hu
-
Yanqi Wang
-
Wugan Lu
-
July 20, 2026
Clinical Scorecard: Metagenomic and Metabolomic Analysis in Primary Aldosteronism Associated with Obstructive Sleep Apnea
At a Glance
| Category | Detail |
|---|
| Condition | Primary Aldosteronism with Obstructive Sleep Apnea |
| Key Mechanisms | Gut microbiome alterations linked to cardiometabolic risk. |
| Target Population | Adults with clinically confirmed Primary Aldosteronism and varying severity of Obstructive Sleep Apnea. |
| Care Setting | Prospective observational study. |
Key Highlights
- Primary aldosteronism frequently coexists with obstructive sleep apnea.
- Gut microbiome alterations may reflect clinical heterogeneity in PA with OSA.
- No significant association found between AHI and overall gene richness or alpha diversity.
- Fecal metabolomic profiling revealed nominal phenotype-associated differences.
- Findings are exploratory and require larger controlled cohorts for validation.
Guideline-Based Recommendations
Diagnosis
- Screening for primary aldosteronism in all individuals with hypertension.
Management
- Consider the relationship between aldosterone status and OSA severity in resistant hypertension.
Monitoring & Follow-up
- Assess gut microbiome and metabolomic profiles in patients with PA and OSA.
Risks
- Higher rates of cardiovascular events in patients with PA compared to those with essential hypertension.
Patient & Prescribing Data
Adults with primary aldosteronism and obstructive sleep apnea.
Exploratory associations between gut microbiome and metabolic signals in PA with OSA.
Clinical Best Practices
- Incorporate dietary assessment and medication exposure in future studies.
- Utilize longitudinal validation to confirm findings.
Related Resources & Content
